Highly sensitive biomarker panels
AssigneeSingulex, Inc.
InventorsPhilippe J. Goix, Robert Puskas, John Todd, Richard Livingston, Douglas Held, Sara Le
Life of this patent
Estimating the term…
Abstract
Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNFα, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF.
Claims17
A method for detecting or monitoring a cardiovascular condition associated with cardiomyocyte damage in a subject, comprising detecting the concentration of two or more biomarkers in a sample from the subject, wherein the biomarkers comprise Troponin-I (cTnI) and Interleukin 17a (IL-17a), and wherein the limit of detection of at least one biomarker is less than about 20 pg/ml, comparing the concentration of the biomarkers to threshold concentrations for the biomarkers, and determining the presence of the cardiovascular condition when the concentration of the biomarkers in the sample is greater than the threshold concentrations.
A method for detecting congestive heart failure in a subject, comprising detecting whether the level of two or more members of a panel of biomarkers in a sample from a subject are elevated compared to the level of the two or more biomarkers in a normal population, wherein the members of the panel comprise Troponin-I (cTnI) and Interleukin 17a (IL-17a), and wherein the limit of detection of at least one member of the panel is less than about 20 pg/ml.
Dependencies are inferred from the claim text.